Wancai Que

Dr. Wancai Que


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
HLHailing Lin
Hailing Lin
HQHongqiang Qiu
Hongqiang Qiu
YCYu Cheng
Yu Cheng
MLMaobai Liu
Maobai Liu
MCMaohua Chen
Maohua Chen
WQWancai Que
Wancai Que
Gelsemium elegans Benth (GEB), also known as heartbreak grass, is a highly poisonous plant belonging to the family Loganiaceae and genus Gelsemium that has broad application prospects in medicine. This article reviews its chemical components, pharmacological effects, toxicity mechanisms, and research progress in clinical applications in recent years. Indole alkaloids are the main active components of GEB and have a variety of pharmacological and biological functions. They have anti-tumor, anti-inflammatory, analgesic, and immunomodulation properties, with the therapeutic dose being close to the toxic dose. Application of small-dose indole alkaloids fails to work effectively, while high-dose usage is prone to poisoning, aggravating the patient’s conditions. Special caution is needed, especially to observe the changes in the disease condition of the patients in clinical practice. In-depth research on the chemical components and mechanisms of GEB is essential to the development of promising lead compounds and lays the foundation for extensive clinical application and safe usage of GEB in the future.

25 November 2025 in Nature Communications
Verified
Journal Article
Open access
YCYanzhao Chen
Yanzhao Chen
YXYangyin Xue
Yangyin Xue
XXXiaowei Xu
Xiaowei Xu
YSYu Su
Yu Su
XTXidan Tong
Xidan Tong
WGWeiwei Guo
Weiwei Guo
Multidrug-resistant infections and impaired healing in chronic diabetic wounds are major clinical challenges. Photodynamic therapy (PDT) is a promising alternative, but its efficacy is limited by conventional photosensitizers. Here, we design two donor-acceptor-donor (D-A-D) metal-organic frameworks (MOFs) using a tetrazine core to narrow the band gap, which enhances visible-light-driven reactive oxygen species (ROS) generation. These MOFs exhibit superior photocatalytic antibacterial activity over benchmark materials. After functionalization with L-arginine, the resulting composites (e.g., A@Zn-TDP) co-release ROS, nitric oxide (NO), and reactive nitrogen species (RNS) enabling rapid and broad-spectrum bacterial eradication (including against MRSA) at low concentrations (25 μg/mL) while accelerating tissue regeneration. In a male diabetic mouse model, A@Zn-TDP treatment under light reduces bacterial load by >95%, controls inflammation, promotes angiogenesis, and speeds up wound closure. This study establishes tetrazine-based D-A-D MOFs as a rationally designed platform for effective PDT and wound healing, underscoring their clinical translational potential.

28 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
XLXueyong Li
Xueyong Li
BZBingqing Zhang
Bingqing Zhang
YCYu Cheng
Yu Cheng
MCMaohua Chen
Maohua Chen
HLHailing Lin
Hailing Lin
HQHongqiang Qiu
Hongqiang Qiu
Polymyxin B (PMB) is the final option for treating multidrug-resistant Gram-negative bacterial infections. The acceptable pharmacokinetic/pharmacodynamic target is an area under the concentration–time curve across 24 h at a steady state (AUCss,24h) of 50–100 mg·h/L. The limited sampling strategy (LSS) is useful for predicting AUC values. However, establishing an LSS is a time-consuming process requiring a relatively dense sampling of patients. Further, given the variability among different centers, the predictability of LSSs is frequently questioned when it is extrapolated to other clinical centers. Currently, limited data are available on a reliable PMB LSS for estimating AUCss,24h. This study assessed and validated the practicability of LSSs established in the literature based on data from our center to provide reliable and ready-made PMB LSSs for laboratories performing therapeutic drug monitoring (TDM) of PMB. The influence of infusion and sampling time errors on predictability was also explored to obtain the optimal time points for routine PMB TDM. Using multiple regression analysis, PMB LSSs were generated from a model group of 20 patients. A validation group (10 patients) was used to validate the established LSSs. PMB LSSs from two published studies were validated using a dataset of 30 patients from our center. A population pharmacokinetic model was established to simulate the individual plasma concentration profiles for each infusion and sampling time error regimen. Pharmacokinetic data obtained from the 30 patients were fitted to a two-compartment model. Infusion and sampling time errors observed in real-world clinical practice could considerably affect the predictability of PMB LSSs. Moreover, we identified specific LSSs to be superior in predicting PMB AUCss,24h based on different infusion times. We also discovered that sampling time error should be controlled within −10 to 15 min to obtain better predictability. The present study provides validated PMB LSSs that can more accurately predict PMB AUCss,24h in routine clinical practice, facilitating PMB TDM in other laboratories and pharmacokinetics/pharmacodynamics-based clinical studies in the future.

16 April 2024 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
XLXueyong Li
Xueyong Li
YCYu Cheng
Yu Cheng
BZBingqing Zhang
Bingqing Zhang
BCBo Chen
Bo Chen
YCYiying Chen
Yiying Chen
HQHongqiang Qiu
Hongqiang Qiu

6 October 2025 in Oncogenesis
Verified
Journal Article
Open access
PDF file
BSBinghe Sun
Binghe Sun
YLYuting Li
Yuting Li
YWYue Wu
Yue Wu
CWCong Wang
Cong Wang
JZJiawei Zhu
Jiawei Zhu
Guo ChenGuo Chen
Guo Chen
BRCA1, a well-known tumor suppressor, maintains genomic integrity by facilitating homologous recombination (HR) repair and protecting DNA replication forks. However, its roles beyond DNA repair and replication remain largely unexplored. Here, we demonstrate that BRCA1 interacts with the RNA-binding protein PARP13 in the cytoplasm of ovarian cancer cells, with DNA damage enhancing this interaction via DNA-PK. Notably, BRCA1/PARP13 association is essential for cell survival but does not influence DNA repair efficacy following DNA damage. Mechanistically, PARP13 binds and destabilizes the mRNA of the endoplasmic reticulum (ER) membrane protein SEC61G. Upon DNA damage, BRCA1 disrupts PARP13-mediated SEC61G mRNA decay, leading to SEC61G upregulation. Elevated SEC61G levels cause calcium leakage from the ER into the cytosol, activating the pro-survival kinase Akt. These findings identify the BRCA1-PARP13-SEC61G axis as a non-canonical DNA damage response (DDR) pathway and highlight mRNA stability and ER calcium signaling as potential therapeutic targets to overcome chemoresistance. The schematic illustrates the mechanism by which non-canonical BRCA1 promotes cell survival through regulating PARP13-mediated SEC61G mRNA decay. Under DNA damage-free conditions (left panel), SEC61G maintains cellular calcium homeostasis between the endoplasmic reticulum and cytosol to support normal physiological functions. Upon DNA damage induction (right panel), enhanced interaction between BRCA1 and PARP13 attenuates the mRNA degradation activity of PARP13 toward SEC61G, leading to upregulated SEC61G protein expression. The aberrant accumulation of SEC61G triggers endoplasmic reticulum calcium leakage, which subsequently activates the AKT signaling pathway to enhance cell survival capacity.

16 July 2025 in European Journal of Pharmacology
Verified
Journal Article
Open access
HLHailing Lin
Hailing Lin
JLJingping Liu
Jingping Liu
YTYuli Tang
Yuli Tang
BCBiyan Chen
Biyan Chen
XHXitong He
Xitong He
WQWancai Que
Wancai Que
Gastric cancer (GC) is one among the most fatal cancers worldwide. Although immunotherapy has expanded the treatment options for patients with advanced GC, the immunosuppressive tumor microenvironment (TME) of GC renders it resistant to immunotherapy. This underscores the urgent need for strategies to enhance the efficacy of immunotherapies. In this study, we identified a natural compound Koumine, which suppresses GC cancer growth in vivo, however, not in vitro. Koumine markedly reduced collagen (COL21A1, COL3A1, COL13A1, and COL14A1) expression in GC cells and significantly increased T-cell infiltration into the tumors. Mechanistically, Koumine was observed to directly bind to and inhibit the kinase activity of transforming growth factor beta receptor 1 (TGFβR1), thereby suppressing Smad2/3 signaling, which led to the downregulation of collagen proteins and increased anti-tumor immunity. Furthermore, the combination of Koumine with anti-PD1 immune checkpoint inhibitor generated synergistic effects in immune-competent GC mouse models, enhancing CD8+ T-cell infiltration and significantly inhibiting tumor growth. The results of our study suggest that Koumine is a potent agent that may be used to disrupt immune exclusion and optimize immunotherapy in patients with GC.